BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s share price rose 2.6% during mid-day trading on Friday . The company traded as high as $6.01 and last traded at $5.82. Approximately 1,922,707 shares changed hands during trading, an increase of 83% from the average daily volume of 1,049,350 shares. The stock had previously closed at $5.97.

BCRX has been the topic of a number of research reports. Piper Jaffray Companies reiterated an “overweight” rating and set a $15.00 target price (up from $13.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Noble Financial reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 8th. ValuEngine raised shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $9.13.

The firm has a 50 day moving average price of $4.83 and a 200-day moving average price of $6.11. The firm’s market capitalization is $470.50 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.02. BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The firm had revenue of $3.10 million for the quarter, compared to the consensus estimate of $5.79 million. During the same quarter in the previous year, the business posted ($0.22) EPS. The firm’s revenue for the quarter was down 35.4% compared to the same quarter last year. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post ($0.73) EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc raised its holdings in BioCryst Pharmaceuticals by 4.9% during the 2nd quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 860 shares during the last quarter. Principal Financial Group Inc. raised its holdings in BioCryst Pharmaceuticals by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 45 shares during the last quarter. Fox Run Management L.L.C. bought a new position in BioCryst Pharmaceuticals during the 2nd quarter worth approximately $126,000. Janney Montgomery Scott LLC raised its holdings in BioCryst Pharmaceuticals by 4.7% during the 2nd quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock worth $185,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Pacad Investment Ltd. bought a new position in BioCryst Pharmaceuticals during the 2nd quarter worth approximately $196,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price Up -2.6%” was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/08/biocryst-pharmaceuticals-inc-bcrx-stock-price-up-2-6.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.